Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial

Fig. 2

Kaplan–Meier curves of A) PFS and B) OS according to ETS status based on symptoms reported by patients at baseline using the symptom scales of the EORTC QLQ-C30 questionnaire. Compared with symptomatic patients without ETS as a reference, the HR and 95% CI were calculated for each population

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us